Sekrol 30 mg

Form: Syrup
Dosage: 30mg/5ml
Packaging: Bottle 150 ml

Active substance: ambroxol

Form: Syrup


– SEKROL pediatric: concentration of 15 mg ambroxol per 5 ml

– SEKROL adult: concentration of 30 mg ambroxol per 5 ml


– SEKROL pediatric: Bottle containing 100 ml of syrup and a 2.5-5ml measuring spoon

– SEKROL adult: Bottle containing 150 ml of syrup and a 2.5-5ml measuring spoon


Target: Pediatric form: children from 0 to 12 years

Adult form: adults and children from 12 years old

Sekrol is indicated as a mucolytic in the management of acute and chronic respiratory diseases that are characterised by viscid mucoid secretions (such as bronchitis, bronchiectasis, sinusitis).


Pediatric Form

For children under 2 years of age, the treating physician decides to use Sekrol 15mg/5ml individually. In the absence of medical advice, it is not recommended to give the medicine to children under 2 years of age.

For children over 12 years of age, Sekrol is available as a 30mg/5ml syrup.


Adult form (from 12 years old)

30 to 60 ml twice a day (5 to 10 ml twice a day)

Sekrol can be taken with or without food.

The concentration of the active substance in Sekrol adult is twice as high as in the paediatric form. 5 ml of the paediatric form is equivalent to 2.5 ml of the adult form.

Sekrol is suitable for diabetic patients.

Over-the-counter drug

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo ( In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma